890898P
Avanti
DOTMA
Avanti Research™ - A Croda Brand
동의어(들):
1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
25 MG
₩551,145
200 MG
₩1,122,895
About This Item
실험식(Hill 표기법):
C42H84ClNO2
CAS Number:
Molecular Weight:
670.57
MDL number:
UNSPSC 코드:
12352211
NACRES:
NA.25
추천 제품
양식
powder
포장
pkg of 2 × 100 mg (890898P-200mg)
pkg of 1 × 25 mg (890898P-25mg)
제조업체/상표
Avanti Research™ - A Croda Brand
응용 분야
advanced drug delivery
지질 유형
cationic lipids
transfection
배송 상태
dry ice
저장 온도
−20°C
SMILES string
[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]
InChI key
LDGWQMRUWMSZIU-LQDDAWAPSA-M
유사한 제품을 찾으십니까? 방문 제품 비교 안내
애플리케이션
DOTMA is suitable for use as a building block of miRNA delivery system and in the preparation.[1]
생화학적/생리학적 작용
DOTMA is a cationic lipid, used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.[1]
포장
5 mL Clear Glass Sealed Ampule (890898P-200mg)
5 mL Clear Glass Sealed Ampule (890898P-25mg)
법적 정보
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
